Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Outstanding (Weighted Average) (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Shares Outstanding (Weighted Average) data on record, last reported at $94.6 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 38.78% year-over-year to $94.6 million; the TTM value through Dec 2025 reached $94.6 million, up 38.78%, while the annual FY2025 figure was $94.6 million, 38.78% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $94.6 million in Q4 2025 per AMLX's latest filing, up from $93.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $94.6 million in Q4 2025 and bottomed at $6.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $56.5 million, with a median of $67.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 819.93% in 2022, then rose 1.35% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $6.6 million in 2021, then surged by 788.13% to $58.5 million in 2022, then increased by 14.94% to $67.2 million in 2023, then rose by 1.35% to $68.1 million in 2024, then soared by 38.78% to $94.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $94.6 million in Q4 2025, $93.3 million in Q3 2025, and $87.4 million in Q2 2025.